Resolution of Infectious Parameters after Antimicrobial Therapy in Patients with Ventilator-associated Pneumonia
- 1 May 2001
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 163 (6) , 1371-1375
- https://doi.org/10.1164/ajrccm.163.6.2007020
Abstract
Although recommended durations of antimicrobial therapy for ventilator-associated pneumonia (VAP) range from 7 to 21 d, these are not based on prospective studies and little is known about the resolution of symptoms after start of antibiotics. Resolution of these symptoms was investigated in 27 patients. VAP was diagnosed on clinical, radiographic, and microbiological criteria, including quantitative cultures of bronchoalveolar lavage. All patients received appropriate antibiotic therapy. Highest temperatures, leukocyte counts, Pa(O(2))/FI(O(2)) ratios, and semiquantitative cultures of endotracheal aspirates were recorded from start of therapy until Day 14. Resolution was defined as the first day that these parameters fulfilled the following definition: temperature < or = 38 degrees C, leukocytes < or = 10 x 10(9)/L, Pa(O(2))/FI(O(2)) ratio > or = 25 kPa, and no or +1 of bacterial growth of etiologic pathogens in cultures of endotracheal aspirate. VAP was caused by Enterobacteriaceae (n = 14), P. aeruginosa (n = 7), S. aureus (n = 6), H. influenzae (n = 3), and S. pneumoniae (n = 1). H. influenzae and S. pneumoniae were eradicated from tracheal aspirates, whereas Enterobacteriaceae, S. aureus, and P. aeruginosa persisted, despite in vitro susceptibility to antibiotics administered. Significant improvements were observed for all clinical parameters, most apparently within the first 6 d after start of antibiotics. Newly acquired colonization, especially with P. aeruginosa and Enterobacteriaceae, occurred in the second week of therapy. Six patients developed a recurrent episode of VAP, four of them with P. aeruginosa. Clinical responses to therapy for VAP occur within the first 6 d of therapy, endotracheal colonization with Gram-negative bacteria persists despite susceptibility to therapy, and acquired colonization usually occurs in the second week of therapy and frequently precedes a recurrent episode.Keywords
This publication has 16 references indexed in Scilit:
- Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated PneumoniaAnnals of Internal Medicine, 2000
- Implementation of Bronchoscopic Techniques in the Diagnosis of Ventilator-associated Pneumonia to Reduce Antibiotic UseAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Indications for antibiotic use in ICU patients: a one-year prospective surveillanceJournal of Antimicrobial Chemotherapy, 1997
- Impact of BAL Data on the Therapy and Outcome of Ventilator-Associated PneumoniaChest, 1997
- The Prevalence of Nosocomial Infection in Intensive Care Units in EuropeJAMA, 1995
- Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stayThe American Journal of Medicine, 1993
- Follow-up Protected Specimen Brushes to Assess Treatment in Nosocomial PneumoniaAmerican Review of Respiratory Disease, 1993
- Diagnosis of Ventilator-associated Pneumonia by Bacteriologic Analysis of Bronchoscopic and Nonbronchoscopic “Blind” Bronchoalveolar Lavage FluidAmerican Review of Respiratory Disease, 1991
- Detection of Nosocomial Lung Infection in Ventilated Patients: Use of a Protected Specimen Brush and Quantitative Culture Techniques in 147 PatientsAmerican Review of Respiratory Disease, 1988
- APACHE IICritical Care Medicine, 1985